Zivin J A, Lyden P D, DeGirolami U, Kochhar A, Mazzarella V, Hemenway C C, Johnston P
Neurology Service, Veterans Administration Medical Center, La Jolla, CA.
Arch Neurol. 1988 Apr;45(4):387-91. doi: 10.1001/archneur.1988.00520280033012.
Tissue plasminogen activator (tPA) has become available for pharmacologic use, and it appears to produce relatively fewer hemorrhagic complications than the previously available, less specific thrombolytic agents. We tested the effects of tPA in several models of embolic stroke and found that neurologic damage was reduced when the drug was administered as late as 45 minutes after cerebral embolic occlusion. The mechanism of therapeutic efficacy of tPA was probably thrombolysis. Drug-induced hemorrhages did not occur when therapy was started within four hours after the onset of vascular occlusion. These results suggest that tPA may be useful for thrombolytic therapy of embolic stroke if the drug is administered rapidly after the onset of vascular occlusion.
组织型纤溶酶原激活剂（tPA）已可用于药物治疗，而且与先前可用的、特异性较低的溶栓剂相比，它似乎产生的出血并发症相对较少。我们在几种栓塞性中风模型中测试了tPA的效果，发现当在脑栓塞闭塞后长达45分钟时给予该药物，神经损伤会减轻。tPA治疗效果的机制可能是溶栓。当在血管闭塞发作后四小时内开始治疗时，未发生药物引起的出血。这些结果表明，如果在血管闭塞发作后迅速给予tPA，它可能对栓塞性中风的溶栓治疗有用。
